CHM and choroideremia: Subretinal administration of AAV2 vectors encoding the REP1 protein (AAV2.REP1) was demonstrated by MacLaren et al. to increase retinal sensitivity in 5 out of 6 patients and substantially improve visual acuity and rod and cone function in the 2 patients with the most advanced choroideremia [95].